Evidence map›Paper›PMID 34860673›Full record

Trial reportJournal of medical Internet research2021

Clinical Efficacy and Psychological Mechanisms of an App-Based Digital Therapeutic for Generalized Anxiety Disorder: Randomized Controlled Trial.

Alexandra Roy, Elizabeth A Hoge, Pablo Abrante, Susan Druker, Tao Liu, Judson A Brewer

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of medical Internet research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03683472 (Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03683472 nacompletednot on this map

Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder

TypeinterventionalSponsorMindSciences, Inc.Ran2019 to 2019Enrolled65ConditionsAnxiety DisordersArmsUnwinding Anxiety Phone App
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Digital therapeutics in the clinic.Bioengineering & translational medicine · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexandra RoyDepartment of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States.ORCID 0000-0002-8065-2177
Elizabeth A HogeDepartment of Psychiatry, Georgetown University Medical Center, Washington, DC, United States.ORCID 0000-0002-5513-2292
Pablo AbranteDepartment of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States.ORCID 0000-0002-4843-3062
Susan DrukerDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.ORCID 0000-0001-9854-4505
Tao LiuDepartment of Biostatistics, Brown University School of Public Health, Providence, RI, United States.ORCID 0000-0002-5274-4445
Judson A BrewerDepartment of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States.ORCID 0000-0001-8984-6704

Funding

Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety DisorderR41MH118130 · NIMH · MINDSCIENCES, INC. · PI BREWER, JUDSON A · 2018 to 2018
$339k
NIMH NIH HHS R41 MH118130
6 · The paper itself

Abstract

backgroundCurrent treatments for generalized anxiety disorder (GAD) often yield suboptimal outcomes, partly because of insufficient targeting of underlying psychological mechanisms (eg, avoidance reinforcement learning). Mindfulness training (MT) has shown efficacy for anxiety; yet, widespread adoption has been limited, partly because of the difficulty in scaling in-person-based delivery. Digital therapeutics are emerging as potentially viable treatments; however, very few have been empirically validated.

objectiveThe aim of this study is to test the efficacy and mechanism of an app-delivered MT that was designed to target a potential mechanism of anxiety (reinforcement learning), based on which previous studies have shown concern regarding feedback and the perpetuation of anxiety through negative reinforcement.

methodsIndividuals with GAD were recruited using social media advertisements and randomized during an in-person visit to receive treatment as usual (n=33) or treatment as usual+app-delivered MT (Unwinding Anxiety; n=32). The latter was composed of 30 modules to be completed over a 2-month period. Associated changes in outcomes were assessed using self-report questionnaires 1 and 2 months after treatment initiation.

resultsWe randomized 65 participants in this study, and a modified intent-to-treat approach was used for analysis. The median number of modules completed by the MT group was 25.5 (IQR 17) out of 30; 46% (13/28) of the participants completed the program. In addition, the MT group demonstrated a significant reduction in anxiety (GAD-7) compared with the control group at 2 months (67% vs 14%; median change in GAD-7: -8.5 [IQR 6.5] vs -1.0 [IQR 5.0]; P<.001; 95% CI 6-10). Increases in mindfulness at 1 month (nonreactivity subscale) mediated decreases in worry at 2 months (Penn State Worry Questionnaire; P=.02) and decreases in worry at 1 month mediated reductions in anxiety at 2 months (P=.03).

conclusionsTo our knowledge, this is the first report on the efficacy and mechanism of an app-delivered MT for GAD. These findings demonstrate the clinical efficacy of MT as a digital therapeutic for individuals with anxiety (number needed to treat=1.6). These results also link recent advances in our mechanistic understanding of anxiety with treatment development, showing that app-delivered MT targets key reinforcement learning pathways, resulting in tangible, clinically meaningful reductions in worry and anxiety. Evidence-based, mechanistically targeted digital therapeutics have the potential to improve health at a population level at a low cost.

trial registrationClinicalTrials.gov NCT03683472; https://clinicaltrials.gov/ct2/show/NCT03683472.

Indexed as

Mobile ApplicationsAnxiety DisordersHumansTreatment Outcomeanxietydigital therapeuticsgeneralized anxiety disordermHealthmindfulnessmobile phoneworry

Identifiers

PMID34860673
PMCPMC8686411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.